Literature DB >> 25227789

Clinicopathologic features predicting involvement of non- sentinel axillary lymph nodes in Iranian women with breast cancer.

Seyed Alireza Moosavi1, Afshin Abdirad, Ramesh Omranipour, Maryam Hadji, Amirnader Emami Razavi, Massoome Najafi.   

Abstract

BACKGROUND: Almost half of the breast cancer patients with positive sentinel lymph nodes have no additional disease in the remaining axillary lymph nodes. This group of patients do not benefit from complete axillary lymph node dissection. This study was designed to assess the clinicopathologic factors that predict non-sentinel lymph node metastasis in Iranian breast cancer patients with positive sentinel lymph nodes.
MATERIALS AND METHODS: The records of patients who underwent sentinel lymph node biopsy, between 2003 and 2012, were reviewed. Patients with at least one positive sentinel lymph node who underwent completion axillary lymph node dissection were enrolled in the present study. Demographic and clinicopathologic characteristics including age, primary tumor size, histological and nuclear grade, lymphovascular invasion, perineural invasion, extracapsular invasion, and number of harvested lymph nodes, were evaluated.
RESULTS: The data of 167 patients were analyzed. A total of 92 (55.1%) had non-sentinel lymph node metastasis. Univariate analysis of data revealed that age, primary tumor size, histological grade, lymphovascular invasion, perineural invasion, extracapsular invasion, and the number of positive sentinel lymph nodes to the total number of harvested sentinel lymph nodes ratio, were associated with non-sentinel lymph node metastasis. After logistic regression analysis, age (OR=0.13; 95% CI, 0.02-0.8), primary tumor size (OR=7.7; 95% CI, 1.4-42.2), lymphovascular invasion (OR=19.4; 95% CI, 1.4- 268.6), extracapsular invasion (OR=13.3; 95% CI, 2.3-76), and the number of positive sentinel lymph nodes to the total number of harvested sentinel lymph nodes ratio (OR=20.2; 95% CI, 3.4-121.9), were significantly associated with non-sentinel lymph node metastasis.
CONCLUSIONS: According to this study, age, primary tumor size, lymphovascular invasion, extracapsular invasion, and the ratio of positive sentinel lymph nodes to the total number of harvested sentinel lymph nodes, were found to be independent predictors of non-sentinel lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25227789     DOI: 10.7314/apjcp.2014.15.17.7049

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Factors Influencing Non-sentinel Node Involvement in Sentinel Node Positive Patients and Validation of MSKCC Nomogram in Indian Breast Cancer Population.

Authors:  Naveen Padmanabhan; Muhamed Faizal Ayub; Khadher Hussain; Ann Kurien; Selvi Radhakrishna
Journal:  Indian J Surg Oncol       Date:  2015-12-05

2.  Predictive Factors for Non-Sentinel Lymph Node Metastasis in the Case of Positive Sentinel Lymph Node Metastasis in Two or Fewer Nodes in Breast Cancer.

Authors:  Chie Toshikawa; Yu Koyama; Masayuki Nagahashi; Kumiko Tatsuda; Kazuki Moro; Junko Tsuchida; Miki Hasegawa; Toshiyuki Niwano; Naoko Manba; Mayuko Ikarashi; Hitoshi Kameyama; Takashi Kobayashi; Shin-Ichi Kosugi; Toshifumi Wakai
Journal:  J Clin Med Res       Date:  2015-06-09

3.  Comparison of clinicopathological characteristics of lymph node positive and lymph node negative breast cancer.

Authors:  Naila Irum Hadi; Qamar Jamal
Journal:  Pak J Med Sci       Date:  2016 Jul-Aug       Impact factor: 1.088

4.  Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments.

Authors:  Manasi P Jogalekar; Elba E Serrano
Journal:  PeerJ       Date:  2018-02-16       Impact factor: 2.984

5.  Analysis of factors related to N2- or N3-stage breast cancer associated with 1-2 positive sentinel lymph nodes in Chinese patients.

Authors:  Ming Luo; Huiming Yuan; Cheng Long; Ka Su; Fu Li; Jian Zeng
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.